Clinical trials examining the efficacy of omalizumab therapy have reported that there are limitations to the current diagnostic methods for atopic asthma based on serum IgE levels and intradermal reactions (Humbert et al., 1996; Menz et al., 1998; de Weck, 2002; Chung et al., 2014). This evidence concerns the gene IGHE and atopic asthma.